WARP

WARP: A multicentre prospective randomised trial of thrombosis prophylaxis with warfarin in cancer patients with central venous catheter

Chief Investigators:	Ms Annie Young
Sponsor:	University of Birmingham
Funder:	Cancer Research UK
Disease Site:	Mixed Primary Cancer
Trial Type:	Trial of an Investigational Medicinal Product
Status:	Complete
UKCRN Study ID:	782
ISRCTN Referance Number:	ISRCTN50312145
Open to New Sites?	No
Recruitment Start Date:	19-Oct-1999
Recruitment End Date:	17-Dec-2004
CRCTU Trial Management Team:	Late Phase Trial Management Team - A
Trial Email Address:	can-crctu-teama@adf.bham.ac.uk

RWARP is a large, simple randomised trial based on the ‘uncertainty principle’ and aims to produce reliable evidence of the utility of warfarin (no warfarin [arm A] vs. warfarin) in cancer patients with CVCs.  Differing doses of warfarin in thrombosis prophylaxis will also be investigated - fixed dose warfarin (1mg/day) [arm B] vs. an individualised dose of warfarin (to maintain INR between 1.5 and 2.0) [arm C].  Randomising 1400 patients to this trial will produce reliable evidence of both utility and optimal dose. The primary endpoint of the trial is the number of thrombotic events (confirmed radiologically). The secondary endpoints are catheter longevity, cost, trial-related toxicity and patient survival across the three arms

Please note that the trials team cannot give individual’s clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible

Trial Summary

• View Trial Summary Document

Trial Protocol

• View Trial Protocol Document

Please Note:
Clinical trial protocols are complex technical documents which should only be used for the treatment of subjects taking part in the trial.